Jane Mattei1, Rodrigo Donalisio da Silva1, David Sehrt1, Wilson R Molina1, Fernando J Kim2. 1. Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States. 2. Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States. Electronic address: fernando.kim@dhha.org.
Abstract
BACKGROUND: Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma. METHODS: MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review. CONCLUSION: The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare. Published by Elsevier Ireland Ltd.
BACKGROUND: Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma. METHODS: MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review. CONCLUSION: The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare. Published by Elsevier Ireland Ltd.
Authors: Elena Verzoni; Paolo Grassi; Isabella Testa; Roberto Iacovelli; Pamela Biondani; Enrico Garanzini; Filippo De Braud; Giuseppe Procopio Journal: Pharmgenomics Pers Med Date: 2014-03-27
Authors: Ki Cheong Park; Jun Hyeok Heo; Jeong Yong Jeon; Hye Ji Choi; A Ra Jo; Seung Won Kim; Ho Jeong Kwon; Sung Joon Hong; Kyung Seok Han Journal: BMC Cancer Date: 2015-01-23 Impact factor: 4.430